MediFocus:分子イメージングの未来...市場調査レポートについてご紹介

【英文タイトル】MediFocus: Future of Molecular Imaging

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 13
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
3 Overview 19
3.1 What is Molecular Imaging? 19
3.2 What are Molecular Imaging Probes? 20
3.3 Growth of Molecular Imaging 21
3.4 Imaging Techniques 22
3.4.1 Overview 22
3.4.2 Positron Emission Tomography (PET) 24
3.4.3 Single Photon Emission Computed Tomography (SPECT) 30
3.4.4 Computed Tomography 32
3.4.5 Magnetic Resonance Imaging 33
3.4.6 Ultrasound Imaging 35
3.4.7 Other Emerging Techniques 37
3.5 Applications of MI 39
3.5.1 Overview 39
3.5.2 Oncology 39
3.5.3 Cardiology 41
3.5.4 Neurology 42
4 Unmet Needs Analysis 43
4.1 Overview 43
4.2 Radiation Exposure 43
4.3 Instrumentation Improvement 44
4.4 Lack of Multidisciplinary-Trained Professionals 45
4.5 Standardization 46
5 Market Opportunity Analysis 48
5.1 Probes for Image-Guided Surgery 48
5.2 Gallium-68 49
5.3 Low-Cost PET Systems 50
5.4 Molecular Imaging in Infectious Disease 52
5.5 Hybrid Imaging 53
5.6 Longer-Lived Isotopes 55
5.7 Role of Imaging Probes in Drug Development 56
6 Market Drivers and Barriers 58
6.1 Overview 58
6.2 Driver: Increased Prevalence of Diseases 58
6.3 Driver: Enthusiasm Surrounding Personalized Medicine 59
6.4 Driver: Hyperpolarized MRS with 13C Holds Promise 59
6.5 Driver: MI Applied to Drug Discovery and Development 60
6.6 Barrier: Regulatory Burden 61
6.7 Barrier: Cost 63
6.8 Barrier: Reimbursement 64
6.9 Barrier: Imaging Probe Production and Distribution Network 65
6.10 Barrier: Predicted 99mTc Shortage 67
6.11 Barrier: Reduced Hospital Budgets 68
6.12 Barrier: Limited Practical Value of Diagnostics in the Absence of Therapeutics 68
6.13 Barrier: Increased Consciousness Regarding Radiation Dose 71
7 Imaging Probes Assessment 73
7.1 Overview 73
7.2 Small Molecules 74
7.2.1 Overview 74
7.2.2 SWOT Analysis 75
7.2.3 [18F]Fluoro-2-deoxy-2-D-glucose ([18F]FDG) 75
7.2.4 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) 79
7.2.5 [18F]Fluoromisonidazole ([18F]FMISO) 82
7.2.6 1-(5-[18F]Fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole ([18F]FAZA) 85
7.2.7 L-3,4-Dihydroxy-6-[18F]fluorophenylalanine ([18F]FDOPA) 88
7.2.8 [18F]Sodium flouride ([18F]NaF) 90
7.2.9 [11C]Acetate 93
7.2.10 N-Methyl-[11C]-2-(4′-methylaminophenyl)-6-hydroxybenzothiasole ([11C]PiB) 96
7.3 Peptides 99
7.3.1 Overview 99
7.3.2 SWOT Analysis 100
7.4 Nanoparticles 100
7.4.1 Overview 100
7.4.2 Types of Nanoparticles for Molecular Imaging 101
7.4.3 SWOT Analysis 102
7.5 Engineered Proteins 103
7.5.1 Overview 103
7.5.2 SWOT Analysis 104
7.6 Aptamers 104
7.6.1 Overview 104
7.6.2 SWOT Analysis 105
8 Probes Pipeline Assessment 106
8.1 Overview 106
8.2 [18F]flurpiridaz (Lantheus Medical Imaging) 106
8.2.1 Overview 106
8.2.2 SWOT Analysis 107
8.3 NAV4694 (Navidea Biopharmaceuticals) 108
8.3.1 Overview 108
8.3.2 SWOT Analysis 109
8.4 [18F]flutemetamol (GE Healthcare) 109
8.4.1 Overview 109
8.4.2 SWOT Analysis 110
8.5 [18F]florbetaben (Piramal Imaging) 111
8.5.1 Overview 111
8.5.2 SWOT Analysis 111
8.6 REDECTANE (Wilex) 112
8.6.1 Overview 112
8.6.2 SWOT Analysis 113
9 Current and Future Players 114
9.1 Overview 114
9.2 Navidea Biopharmaceuticals 115
9.2.1 Overview 115
9.2.2 Portfolio Assessment 115
9.2.3 SWOT Analysis 118
9.3 Lantheus Medical Imaging 119
9.3.1 Overview 119
9.3.2 Portfolio Assessment 119
9.3.3 SWOT Analysis 121
9.4 Mallinckrodt Pharmaceuticals 122
9.4.1 Overview 122
9.4.2 Portfolio Assessment 122
9.4.3 SWOT Analysis 124
9.5 Avid Radiopharmaceuticals (Eli Lilly) 124
9.5.1 Overview 124
9.5.2 Portfolio Assessment 125
9.5.3 SWOT Analysis 127
9.6 Bracco Imaging 128
9.6.1 Overview 128
9.6.2 Portfolio Assessment 128
9.6.3 Product Recalls 129
9.6.4 SWOT Analysis 130
9.7 GE Healthcare 130
9.7.1 Overview 130
9.7.2 Portfolio Assessment 131
9.7.3 SWOT Analysis 133
9.8 Piramal Imaging 134
9.8.1 Overview 134
9.8.2 Portfolio Assessment 134
9.8.3 SWOT Analysis 135
9.9 Siemens 135
9.9.1 Overview 135
9.9.2 Portfolio Assessment 135
9.9.3 SWOT Analysis 137
9.10 Novelos Therapeutics 137
9.10.1 Overview 137
9.10.2 Portfolio Assessment 138
9.10.3 SWOT Analysis 139
9.11 Affibody 139
9.11.1 Overview 139
9.11.2 Portfolio Assessment 139
9.11.3 SWOT Analysis 140
9.12 Atreus Pharmaceuticals 141
9.12.1 Overview 141
9.12.2 Portfolio Assessment 141
9.12.3 SWOT Analysis 142
9.13 Kereos 142
9.13.1 Overview 142
9.13.2 Portfolio Assessment 142
9.13.3 SWOT Analysis 143
9.14 Progenics Pharmaceuticals 143
9.14.1 Overview 143
9.14.2 Portfolio Assessment 143
9.14.3 SWOT Analysis 145
9.15 FluoroPharma Medical 145
9.15.1 Overview 145
9.15.2 Portfolio Assessment 145
9.15.3 SWOT analysis 147
9.16 Wilex 147
9.16.1 Overview 147
9.16.2 Portfolio Assessment 148
9.16.3 SWOT analysis 149
9.17 Radiopharmaceutical Suppliers and Distributors 150
9.17.1 Supply-Chain Overview 150
9.17.2 Nordion 151
9.17.3 Positron 152
9.17.4 Cardinal Health 153
9.17.5 Advanced Accelerator Applications (AAA) 154
9.18 Other Companies 156
9.19 Key Deals, Partnerships, and Agreements 157
10 Appendix 158
10.1 Bibliography 158
10.2 Definitions 173
10.3 Abbreviations 174
10.4 Research Methodology 177
10.4.1 Overview 177
10.4.2 Coverage 177
10.4.3 Secondary Research 178
10.5 Physicians and Specialists Included in this Study 179
10.6 Primary Research 180
10.7 About the Authors 181
10.7.1 Analysts 181
10.7.2 Global Head of Healthcare 182
10.8 Disclaimer 183


【レポート販売概要】

■ タイトル:MediFocus:分子イメージングの未来
■ 英文:MediFocus: Future of Molecular Imaging
■ 発行日:2013年8月31日
■ 調査会社:GlobalData
■ 商品コード:GDATA403161860
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。